Results 131 to 140 of about 22,968 (195)

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

Three-dimensional structure of the palbociclib-HIV TAR complex. [PDF]

Nucleic Acids Res
Ramireddy RR, Vidalala V, Chaubey B, Olsen GL, Varani G.   +4 more
europepmc   +1 more source

Cyclin-Dependent 4/6 Kinase Inhibitors for Treatment of HER2-Positive Breast Cancer: 2026 Update. [PDF]

Cancers (Basel)
O'Sullivan CC.
europepmc   +1 more source

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial. [PDF]

Nat Commun
Matikas A, Tzoras E, Sarafidis M, Sifakis EG, Bjöhle J, Barnekow E, Margolin S, Isaksson-Friman E, Kessler LE, Zouzos A, Johansson H, Hellström M, Agartz S, Grybäck P, Salgkamis D, Zerdes I, Wang K, Hartman J, Acs B, Sun W, Boyaci C, Villacampa G, Pascual T, Gavila J, Prat A, Perou C, Brandberg Y, Bergh J, Hatschek T, Foukakis T.   +29 more
europepmc   +1 more source

Targeting cell cycle in leukemia: "Is palbociclib the game-changer?": A review. [PDF]

Medicine (Baltimore)
Azizan MA, Abeden Z, Shamsuddin NHN, Ahid F, Mohd Yusoff N, Ismail MN, Ng SK, Isa A.   +7 more
europepmc   +1 more source

MEK + CDK4 a regimen for non-BRAF V6000 melanoma [PDF]

, 2015
Jeff Sosman
core   +1 more source

Palbociclib in Combination with Endocrine Therapy in Patients with Metastatic Breast Cancer in a Real-World Population: Impact of Dose-Intensity, Dose Reductions and Cycle Delays on Efficacy. [PDF]

Curr Oncol
Coussirou J, Grenier J, Mege A, Arnaud A, De Crozals F, Bonnet E, Vazquez L.   +6 more
europepmc   +1 more source

Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment. [PDF]

Sci Rep
Takada S, Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Tahatsu K, Kitagawa Y, Tsuchiya M, Kitahora M, Umehara K, Nagayama A, Kosaka S, Asano-Niwa Y, Watanabe K, Seki T, Ohnuki K, Futamura M, Kawazoe H, Nakamura T.   +21 more
europepmc   +1 more source

Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors. [PDF]

J Pers Med
Poli I, Oliva GR, Mongelli G, Rotondi A, Frescura V, Arcuri G, Garufi G, Pontolillo L, Mastrantoni L, Di Monte E, Maliziola N, Fucile MA, Salvatori F, Mondello R, Palazzo A, Fabi A, Bria E, Tortora G, Orlandi A.   +18 more
europepmc   +1 more source

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study). [PDF]

Breast Cancer
Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Muramatsu Y, Kosaka N, Masuda N.   +22 more
europepmc   +1 more source